Volume 4.46 | Nov 22

Mammary Cell News 4.46 November 22, 2012
Mammary Cell News
     In this issue: Publications | Reviews Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Host Epithelial Geometry Regulates Breast Cancer Cell Invasiveness
Researchers explored how the biophysical characteristics of the host microenvironment affect the proliferative and invasive tumor phenotype of the earliest stages of tumor development, by using a 3D microfabrication-based approach to engineer ducts composed of normal mammary epithelial cells that contained a single tumor cell. [Proc Natl Acad Sci USA] Abstract | Full Article

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more - 645x110
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

A Preclinical Mouse Model of Invasive Lobular Breast Cancer Metastasis
The authors report the development of a mouse model of spontaneous breast cancer metastasis which recapitulates key events in its formation and clinical course. [Cancer Res] Abstract

Tumor Associated Macrophages Regulate Murine Breast Cancer Stem Cells through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
Scientists report that tumor-associated macrophages promote cancer stem cell-like phenotypes in murine breast cancer cells by upregulating their expression of Sox-2. [Stem Cells] Abstract

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
The authors investigated the role of interleukin-8 in the regulation of cancer stem-like cells activity using patient-derived breast cancers and determined the potential benefit of combining CXCR1/2 inhibition with HER2-targeted therapy. [Clin Cancer Res] Abstract

CLOCK Is a Substrate of SUMO and Sumoylation of CLOCK Upregulates the Transcriptional Activity of Estrogen Receptor-α
Scientists showed that circadian locomotor output cycles kaput (CLOCK), a key circadian protein, can interact with estrogen receptor-α. Furthermore, this interaction was enhanced by estrogen. [Oncogene] Abstract

Class IIa HDACs Repressive Activities on MEF2-Dependent Transcription Are Associated with Poor Prognosis of ER+ Breast Tumors
The authors found that class IIa HDACs are heterogeneously expressed and display redundant activities in breast cancer cells. [FASEB J] Abstract

TCPTP Regulates Src Family Protein Tyrosine Kinases and STAT3 Signaling and Is Lost in Triple Negative Breast Cancers
Scientists report that TCPTP protein levels are decreased in a subset of breast cancer cell lines in vitro and that TCPTP protein is absent in a large proportion of ‘triple negative’ primary human breast cancers. [Mol Cell Biol] Abstract

Loss of Pigment Epithelium-Derived Factor: A Novel Mechanism for the Development of Endocrine Resistance in Breast Cancer
The authors investigated the role of pigment epithelium-derived factor in the development of endocrine resistance in breast cancer. [Breast Cancer Res] Abstract | Full Article

Heparins Modulate the IFN-γ-Induced Production of Chemokines in Human Breast Cancer Cells
Researchers tested whether heparins had an impact on the chemokines CXCL9 and CXCL10 as well as the IFN-γ signaling in human breast cancer cells in vitro. [Breast Cancer Res Treat] Abstract

CLINICAL RESEARCH

Risk of Metachronous Breast Cancer after BRCA Mutation-Associated Ovarian Cancer
The authors sought to estimate the risk of breast cancer after a diagnosis of ovarian cancer associated with mutation of the BRCA1/2 (breast cancer, early onset) genes. [Cancer] Abstract

The Risk of Primary and Contralateral Breast Cancer after Ovarian Cancer in BRCA1/BRCA2 Mutation Carriers
The objective of this study was to assess the incidence of primary breast cancer and contralateral breast cancer in patients who had BRCA1/BRCA2-associated epithelial ovarian cancer. [Cancer] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.

REVIEWS

Management of the Axilla in Early Breast Cancer Patients in the Genomic Era
Because the integration of novel surgical management and tumor biology is needed, the authors provide an overview of the current challenges that a more detailed knowledge of tumor biology has brought to early breast cancer staging and treatment. [Ann Oncol] Abstract

Stat5 in Breast Cancer: Potential Oncogenic Activity Coincides with Positive Prognosis for the Disease
Nuclear localization of signal transducer and activator of transcription (Stat) 5 marks good prognosis in estrogen receptor/progesterone receptor-positive breast tumors. [Carcinogenesis] Abstract

INDUSTRY NEWS

Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
Valor will combine the assets and resources of Caliber with ImmunGene’s technologies, know-how, and intellectual property (IP). ImmunGene will grant Valor exclusive licenses to its IP for three monoclonal antibody-interferon fusion product candidates in various stages of preclinical development. Caliber will commit sufficient funds to enable Valor to reach certain development milestones for these compounds in the treatment of non-Hodgkin’s lymphoma, multiple myeloma, and breast cancer. [PR Newswire Association LLC] Press Release

Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products
Colby Pharmaceutical Company and MannKind Corporation announced a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s novel MKC1106 active immunotherapy programs, which are currently being developed for the treatment of melanoma, prostate, hematological disorders and other human cancers. [MannKind Corporation] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Keystone Symposia: Tumor Metabolism
Keystone, United States
February 24-March 1, 2013

Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Postdoctoral Fellow – Cancer Genomics (Mayo Clinic Florida)

Assistant Professor – Breast Cancer (Cedars-Sinai Medical Center)

Principal Investigator – Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position – Genetic Biomarkers in Breast Cancer (Rush University Medical Center)


Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us